

Uwe Pelzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2018528/publications.pdf>

Version: 2024-02-01

86
papers

4,204
citations

201385

27
h-index

114278

63
g-index

94
all docs

94
docs citations

94
times ranked

5674
citing authors

#	ARTICLE	IF	CITATIONS
1	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 545-557.	6.3	878
2	Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 2423-2429.	0.8	397
3	Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group. <i>European Journal of Cancer</i> , 2011, 47, 1676-1681.	1.3	318
4	Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2028-2034.	0.8	217
5	CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 3330-3337.	0.8	215
6	Detection of recurrent pancreatic cancer: Comparison of FDG-PET with CT/MRI. <i>Pancreatology</i> , 2005, 5, 266-272.	0.5	152
7	Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. <i>Leukemia</i> , 2018, 32, 1908-1919.	3.3	137
8	APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 4000-4000.	0.8	125
9	±-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. <i>British Journal of Cancer</i> , 2014, 111, 1917-1923.	2.9	119
10	Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 128-138.	3.7	89
11	Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2017, 83, 290-301.	1.3	74
12	Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous	1.1	70
13	SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. <i>Annals of Oncology</i> , 2014, 25, 1025-1032.	0.6	66
14	Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. <i>BMC Cancer</i> , 2010, 10, 86.	1.1	63
15	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1940-1951.	1.9	60
16	The Impact of Simultaneous Liver Resection for Occult Liver Metastases of Pancreatic Adenocarcinoma. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-8.	0.7	57
17	Prognostic Factors for Long-Term Survival in Patients with Ampullary Carcinoma: The Results of a 15-Year Observation Period after Pancreaticoduodenectomy. <i>HPB Surgery</i> , 2014, 2014, 1-8.	2.2	51
18	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology, The</i> , 2018, 19, e151-e160.	5.1	51

#	ARTICLE	IF	CITATIONS
19	A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemo-naïve advanced pancreatic cancer. <i>Annals of Oncology</i> , 2000, 11, 1267-1272.	0.6	48
20	Does long-term survival in patients with pancreatic cancer really exist?-Results from the CONKO-001 study. <i>Journal of Surgical Oncology</i> , 2013, 108, 398-402.	0.8	41
21	Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine – Results from the CONKO-001 trial. <i>European Journal of Cancer</i> , 2015, 51, 1546-1554.	1.3	40
22	Randomized, double-blind, placebo-controlled phase II study of istratimumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). <i>Annals of Oncology</i> , 2020, 31, 79-87.	0.6	36
23	CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks – A prospective randomized phase III study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4007-4007.	0.8	35
24	Safety, Efficacy and Pharmacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study. <i>Cancers</i> , 2020, 12, 3130.	1.7	34
25	A phase Ib/IIa study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 385-385.	0.8	34
26	Cancer-related neuropathic pain in out-patient oncology clinics: a European survey. <i>BMC Palliative Care</i> , 2013, 12, 41.	0.8	32
27	Blood group determinates incidence for pancreatic cancer in Germany. <i>Frontiers in Physiology</i> , 2013, 4, 118.	1.3	29
28	Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2018, 118, 1485-1491.	2.9	29
29	PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. , 2021, 9, e002844.		29
30	Treatment of Intrahepatic Cholangiocarcinoma – A Multidisciplinary Approach. <i>Cancers</i> , 2022, 14, 362.	1.7	29
31	The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. <i>Surgical Oncology</i> , 2018, 27, 688-694.	0.8	28
32	TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3732-3739.	3.2	28
33	Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHC1 expression. <i>Nature Communications</i> , 2022, 13, 156.	5.8	28
34	Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy. <i>Frontiers in Oncology</i> , 2013, 3, 155.	1.3	26
35	Quality-adjusted survival with combination nab-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. <i>British Journal of Cancer</i> , 2017, 116, 1247-1253.	2.9	25
36	Phase I trial of gemcitabine (Gemzar®), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer. <i>Anti-Cancer Drugs</i> , 1999, 10, 699-704.	0.7	24

#	ARTICLE	IF	CITATIONS
37	Second-Line Treatment in Pancreatic Cancer Patients. <i>Pancreas</i> , 2016, 45, 601-605.	0.5	22
38	Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 248.	0.8	22
39	Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study. <i>Oncology Research and Treatment</i> , 2009, 32, 99-102.	0.8	21
40	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology</i> , 2020, 7, e746-e755.	2.2	21
41	P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. <i>Pathology Research and Practice</i> , 2016, 212, 726-734.	1.0	19
42	Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. <i>Frontiers in Oncology</i> , 2021, 11, 670396.	1.3	19
43	Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy. <i>Pancreas</i> , 2015, 44, 930-936.	0.5	18
44	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. <i>BMJ Open</i> , 2016, 6, e010569.	0.8	18
45	Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 258.	0.8	18
46	Prognostic and Predictive Molecular Markers in Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 1026.	1.7	17
47	Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients. <i>PLoS ONE</i> , 2017, 12, e0186341.	1.1	15
48	A tailored approach in lymph node-positive perihilar cholangiocarcinoma. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 1499-1509.	0.8	15
49	Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer – the CONKO 004 pilot trial. <i>BMC Cancer</i> , 2014, 14, 204.	1.1	14
50	The Falciform Ligament for Mesenteric and Portal Vein Reconstruction in Local Advanced Pancreatic Tumor: A Surgical Guide and Single-Center Experience. <i>HPB Surgery</i> , 2018, 2018, 1-8.	2.2	13
51	Routine portal vein resection for pancreatic adenocarcinoma shows no benefit in overall survival. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1094-1099.	0.5	12
52	Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies?. <i>Journal of Clinical Medicine</i> , 2022, 11, 2367.	1.0	12
53	Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study. <i>Archives of Medical Science</i> , 2013, 2, 261-267.	0.4	10
54	Ultrasound Time-Harmonic Elastography of the Pancreas. <i>Investigative Radiology</i> , 2020, 55, 270-276.	3.5	9

#	ARTICLE	IF	CITATIONS
55	Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine-versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP).. Journal of Clinical Oncology, 2018, 36, 348-348.	0.8	9
56	Hent1 expression in patients with pancreatic cancer treated with gemcitabine after curative intended resection: Results from the CONKO-001 trial.. Journal of Clinical Oncology, 2014, 32, 4124-4124.	0.8	8
57	Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemiaâ€”A retrospective analysis. European Journal of Cancer, 2018, 100, 85-93.	1.3	7
58	First-Line Chemotherapy in Advanced Pancreatic Cancer. , 2008, 177, 57-60.		7
59	Role of F18-FDG PET for Monitoring of Radiochemotherapy â€” Estimation of Detectable Number of Tumour Cells. Oncology Research and Treatment, 2004, 27, 287-290.	0.8	6
60	First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group. Cancer Chemotherapy and Pharmacology, 2011, 68, 1173-1178.	1.1	6
61	Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG). BMJ Open, 2020, 10, e035546.	0.8	6
62	First-line nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer from routine clinical practice. In Vivo, 2014, 28, 1135-40.	0.6	6
63	Reply to M.G. McNamara et al and T.H. Oo. Journal of Clinical Oncology, 2016, 34, 516-517.	0.8	5
64	Influence of the body mass index on postoperative outcome and long-term survival after pancreatic resections in patients with underlying malignancy. Hepatobiliary Surgery and Nutrition, 2019, 8, 201-210.	0.7	5
65	Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer â€” A Matched-Pair Analysis. Anticancer Research, 2019, 39, 5781-5787.	0.5	5
66	Influence of Baseline CT Body Composition Parameters on Survival in Patients with Pancreatic Adenocarcinoma. Journal of Clinical Medicine, 2022, 11, 2356.	1.0	5
67	Split-bolus vs. multiphasic contrast bolus protocol in patients with pancreatic cancer or cholangiocarcinoma. European Journal of Radiology, 2019, 119, 108626.	1.2	4
68	Fechtner syndromeâ€”a myosin heavy chain 9 disorderâ€”and pregnancy. International Journal of Gynecology and Obstetrics, 2010, 109, 163-164.	1.0	3
69	Strengths, Weaknesses, Opportunities, and Threats of Centralized Pancreatic Surgery: a Single-Center Analysis of 3000 Consecutive Pancreatic Resections. Journal of Gastrointestinal Surgery, 2019, 23, 492-502.	0.9	3
70	Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma â€” A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials. European Journal of Cancer, 2021, 150, 250-259.	1.3	3
71	Second-Line Chemotherapy in Advanced Pancreatic Cancer. , 2008, 177, 61-64.		3
72	Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. Journal of Surgical Oncology, 2015, 112, 66-71.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, S43-7.	0.8	2
74	The Role of Immunosuppression for Recurrent Cholangiocellular Carcinoma after Liver Transplantation. <i>Cancers</i> , 2022, 14, 2890.	1.7	2
75	Biliary Tract Cancer: A Survey Regarding the Current Oncological Daily Care Practice in Germany. <i>Onkologie</i> , 2012, 35, 755-760.	1.1	1
76	Sequence therapy in metastatic pancreatic cancer. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, 578-582.	0.2	1
77	Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma—Who Will Benefit from a Secondary Resection?. <i>Medicina (Lithuania)</i> , 2021, 57, 77.	0.8	1
78	Influence of cytotoxic tumor-infiltrating T lymphocytes on outcome in resectable pancreatic cancer: Results from the CONKO 001 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 281-281.	0.8	1
79	A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 330-330.	0.8	1
80	CONKO-008: Oxaliplatin (O)/folinic acid (FA)/5-fluorouracil (5-FU) (24h) in combination with lapatinib as second-line therapy in pancreatic cancer after gemcitabine failure: A phase I trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14533-e14533.	0.8	1
81	Is gemcitabine (G) reuse possible in early recurrences after its adjuvant application in pancreatic adenocarcinoma (PA) treatment?. <i>Journal of Clinical Oncology</i> , 2015, 33, e15219-e15219.	0.8	0
82	Outcomes of gemcitabine (Gem)-based palliative first-line therapy in the treatment of recurrent disease or of initially unresectable pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e15218-e15218.	0.8	0
83	Nabpaclitaxel plus gemcitabine in subjects with advanced pancreatic cancer who have cholestatic hyperbilirubinemia secondary to bile duct obstruction.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15717-e15717.	0.8	0
84	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI) in pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with gemcitabine-based therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15732-e15732.	0.8	0
85	A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS524-TPS524.	0.8	0
86	Phase 1b study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS725-TPS725.	0.8	0